X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GH001, is formulated for mebufotenin (5-MeO-DMT) administration via a proprietary inhalation approach, which is investigated for the treatment of treatment-resistant depression.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: GH001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
GH Research will use the proceeds to support further clinical development of GH001 (5-MeO-DMT) in Treatment-Resistant Depression (TRD) and to advance GH001 into further clinical development in additional psychiatric and neurological disorders.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: GH001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 13, 2021
Details:
GH001 has the potential to offer an ultra-rapid clearance of symptoms with long-term sustained remission after a single administration session. In the completed Phase 1 healthy volunteer study (GH001-HV-101), GH001 was safe and well-tolerated at the investigated dose levels.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: GH001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
